TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023 06:05 ET
|
TFF Pharmaceuticals, Inc.
Announced pricing of approximately $5 million equity financing (approximately $5.7 million if underwriter’s overallotment option is exercised in full); expected to extend cash runway through initial...
TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock
August 15, 2023 06:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock
August 14, 2023 16:01 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023
August 09, 2023 08:30 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections
July 31, 2023 07:00 ET
|
TFF Pharmaceuticals, Inc.
Voriconazole Inhalation Powder (TFF VORI) is an investigational, inhaled formulation of voriconazole developed using TFF Pharmaceuticals Thin Film Freezing technology that is currently being evaluated...
TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine
June 26, 2023 07:00 ET
|
TFF Pharmaceuticals, Inc.
National Institute of Health/National Institute of Allergy and Infectious Disease Direct to Phase II SBIR Grant Will Fund Preclinical and IND Enabling Studies on a Shelf-Stable Mucosal Delivered...
TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
May 23, 2023 16:05 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 16:05 ET
|
TFF Pharmaceuticals, Inc.
Initial Phase 2 data for TFF VORI and TFF TAC expected later this yearExpanded compassionate use program for TFF VORIEntered into CRADA with National Institute of Environmental Health Sciences...
TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases
May 04, 2023 08:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program
May 01, 2023 07:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...